BACKGROUND: Almost 40% of people diagnosed with colorectal cancer will die from their disease, most with metastatic spread. When feasible, hepatic resection offers the greatest probability of cure for isolated liver metastases, but there are barriers to curative resection. Those barriers include the extent and distribution of lesions within the liver, extrahepatic disease, comorbidities, and age. Chemotherapy is often administered before or after resection with the intention of improving disease-free and overall survival. The timing of chemotherapy (adjuvant vs. neoadjuvant vs. perioperative) for patients undergoing potentially curative hepatic resection of metastasis of colorectal cancer origin is controversial. METHODS: Colorectal cancer patients with liver metastases resected at The Ottawa Hospital between January 1, 2003, and December 31, 2009, were identified, and their clinical records were retrospectively reviewed. Patients receiving intraoperative radiofrequency ablation (rfa) as part of their management were included. Factors associated with overall and disease-free survival were evaluated. RESULTS: The 168 identified patients (57% men, 43% women) had a median age of 63 years (range: 31-84 years). After hepatectomy, 10% had positive resection margins. Intraoperative rfa was used in 25 patients (15%). Chemotherapy was administered in the neoadjuvant (19%), adjuvant (31%), or "perioperative" (both neoadjuvant and adjuvant, 50%) setting. Use or omission of intraoperative rfa was not associated with a difference in overall survival (hazard ratio: 0.99; 95% confidence interval: 0.53 to 1.84; p = 0.97). CONCLUSIONS: Compared with patients who did not receive chemotherapy, those who received chemotherapy, regardless of timing, experienced improved overall survival and disease-free survival. Use of rfa where required as an adjunct to hepatic resection appears to be effective and is not associated with worse overall survival.
BACKGROUND: Almost 40% of people diagnosed with colorectal cancer will die from their disease, most with metastatic spread. When feasible, hepatic resection offers the greatest probability of cure for isolated liver metastases, but there are barriers to curative resection. Those barriers include the extent and distribution of lesions within the liver, extrahepatic disease, comorbidities, and age. Chemotherapy is often administered before or after resection with the intention of improving disease-free and overall survival. The timing of chemotherapy (adjuvant vs. neoadjuvant vs. perioperative) for patients undergoing potentially curative hepatic resection of metastasis of colorectal cancer origin is controversial. METHODS:Colorectal cancerpatients with liver metastases resected at The Ottawa Hospital between January 1, 2003, and December 31, 2009, were identified, and their clinical records were retrospectively reviewed. Patients receiving intraoperative radiofrequency ablation (rfa) as part of their management were included. Factors associated with overall and disease-free survival were evaluated. RESULTS: The 168 identified patients (57% men, 43% women) had a median age of 63 years (range: 31-84 years). After hepatectomy, 10% had positive resection margins. Intraoperative rfa was used in 25 patients (15%). Chemotherapy was administered in the neoadjuvant (19%), adjuvant (31%), or "perioperative" (both neoadjuvant and adjuvant, 50%) setting. Use or omission of intraoperative rfa was not associated with a difference in overall survival (hazard ratio: 0.99; 95% confidence interval: 0.53 to 1.84; p = 0.97). CONCLUSIONS: Compared with patients who did not receive chemotherapy, those who received chemotherapy, regardless of timing, experienced improved overall survival and disease-free survival. Use of rfa where required as an adjunct to hepatic resection appears to be effective and is not associated with worse overall survival.
Entities:
Keywords:
Colorectal cancer; hepatic resection; radiofrequency ablation; timing of chemotherapy
Authors: Mehrdad Nikfarjam; Serene Shereef; Eric T Kimchi; Niraj J Gusani; Yixing Jiang; Diego M Avella; Rickhesvar P Mahraj; Kevin F Staveley-O'Carroll Journal: Ann Surg Oncol Date: 2008-11-27 Impact factor: 5.344
Authors: Karin Nielsen; Aukje A J M van Tilborg; Martijn R Meijerink; Matessa O Macintosh; Babs M Zonderhuis; Elly S M de Lange; Emile F I Comans; Sybren Meijer; M Petrousjka van den Tol Journal: World J Surg Date: 2013-06 Impact factor: 3.352
Authors: Fredericke H van Duijnhoven; Maarten C Jansen; Jan M C Junggeburt; Richard van Hillegersberg; Arjen M Rijken; Frits van Coevorden; Joost R van der Sijp; Thomas M van Gulik; Gerrit D Slooter; Joost M Klaase; Hein Putter; Rob A E M Tollenaar Journal: Ann Surg Oncol Date: 2006-03-17 Impact factor: 5.344
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321
Authors: Robbert S Puijk; Alette H Ruarus; Laurien G P H Vroomen; Aukje A J M van Tilborg; Hester J Scheffer; Karin Nielsen; Marcus C de Jong; Jan J J de Vries; Babs M Zonderhuis; Hasan H Eker; Geert Kazemier; Henk Verheul; Bram B van der Meijs; Laura van Dam; Natasha Sorgedrager; Veerle M H Coupé; Petrousjka M P van den Tol; Martijn R Meijerink Journal: BMC Cancer Date: 2018-08-15 Impact factor: 4.430
Authors: Martijn R Meijerink; Robbert S Puijk; Aukje A J M van Tilborg; Kirsten Holdt Henningsen; Llenalia Garcia Fernandez; Mattias Neyt; Juanita Heymans; Jacqueline S Frankema; Koert P de Jong; Dick J Richel; Warner Prevoo; Joan Vlayen Journal: Cardiovasc Intervent Radiol Date: 2018-04-17 Impact factor: 2.740